Key Takeaways
- The AtaiBeckley (ATAI) merger with Eli Lilly closed on September 11, 2026
- Shareholders received a cash payment of $6.75 for each share, alongside one contingent value right
- Additional milestone-based payments through CVRs may reach $2.50 per share
- Leading up to the transaction’s closure, AtaiBeckley shares surged approximately 80% over six months, closing at $7.35
- The company initiated its Nasdaq delisting procedures by filing Form 25
Eli Lilly (LLY) finalized its purchase of AtaiBeckley Inc. (ATAI) on Friday, September 11, 2026. The acquired entity now functions as a fully owned Lilly subsidiary.
The transaction structure converted every AtaiBeckley share into a $6.75 cash payment, accompanied by one CVR. The immediate equity valuation reached approximately $2.8 billion.
The contingent value rights may deliver an additional $2.50 per share, potentially elevating the complete transaction valuation to $3.8 billion. These future payments depend on achieving designated clinical development and regulatory approval milestones across multiple years.
The milestone structure includes: a payment of up to $1.00 per share when Phase 3 testing of VLS-01 commences within a four-year window, up to $0.50 per share following U.S. regulatory approval and DEA rescheduling of BPL-003 within five years, and up to $1.00 per share after U.S. approval and DEA rescheduling of VLS-01 within a seven-year timeframe.
The CVRs cannot be transferred between parties and won’t receive any exchange listing. They provide no ownership stakes or voting privileges.
At the transaction’s close, AtaiBeckley shares were valued at $7.35, marginally exceeding the $6.75 immediate cash payment, indicating market expectations regarding CVR potential. The stock experienced an approximately 80% increase during the six-month period preceding the closure.
AtaiBeckley’s Strategic Value for Lilly
AtaiBeckley specializes in advancing fast-acting neuroplastogenic compounds designed for mental health disorders. The company’s primary candidate, BPL-003, addresses treatment-resistant depression.
According to Carole Ho, who leads Lilly’s neuroscience division, the objective centers on transitioning from continuous dosing models toward treatments offering quicker results for individuals who haven’t benefited from current therapeutic options.
Wall Street Analysts Offered Varied Perspectives
Following the initial deal announcement, financial analysts presented divergent viewpoints. Deutsche Bank, H.C. Wainwright, and Jefferies each reduced their AtaiBeckley ratings after the acquisition news.
Deutsche Bank shifted to a Hold rating from Buy, reducing its price objective to $8.00 from $12.00. H.C. Wainwright changed to Neutral from Buy, dramatically lowering its target to $7.50 from $25. Jefferies similarly adopted a Hold stance, decreasing its target to $7.50 from $10.00.
Oppenheimer stood apart from this trend, maintaining its Outperform recommendation with a $16.00 price objective.
AtaiBeckley shareholders voted to approve the transaction at a specially convened meeting prior to the closing.
The entire AtaiBeckley board of directors and executive team resigned at the transaction’s completion. Leadership from Merger Sub, a Lilly controlled entity, assumed these positions.
Corporate governance documents, including the certificate of incorporation and bylaws, underwent modifications consistent with merger requirements. All outstanding equity compensation programs ceased at closing.
AtaiBeckley informed Nasdaq about the merger’s finalization and submitted a request to halt stock trading. The company asked Nasdaq to submit Form 25 to the SEC for delisting purposes. Plans also include filing Form 15 to terminate ongoing SEC disclosure requirements.
LLY shares declined 0.33% during the session, settling at $1,119.26.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
